Table 1.

Number and Percent of Women Enrolled In WHEL across Isoflavone category by Demographic, Medical and Tumor Characteristics

Soy Isoflavone Intake(mg/day)
Baseline Characteristics	Level 1 [0-0.7] median= 0 n (%)	Level 2 (0.7-1.01] median= 0.3 n (%)	Level 3 (1.01-16.33] median= 4.8 n (%)	Level 4 (16.33-86.9] median= 26.7 n (%)	P-value*
Age (years)					0.008
< 45	182(37.9)	192(40)	80(16.7)	26(5.4)
45-54	440(39)	441(39.1)	180(15.9)	68(6)
55-60	179(37.9)	194(41.1)	75(15.9)	24(5.1)
>=60	294(44.9)	267(40.8)	75(11.5)	19(2.9)
Race/Ethnicity					<0.001
White	910(39.0)	951(40.7)	350(15)	123(5.3)
Black	69(65.7)	26(24.8)	9(8.6)	1(1)
Hispanic	91(61.1)	42(28.2)	12(8.1)	4(2.7)
Asian	8(9.5)	45(53.6)	27(32.1)	4(4.8)
Other*	17(26.6)	30(46.9)	12(18.8)	5(7.8)
Education					<0.001
Some college	625(50.2)	455(36.6)	128(10.3)	36(2.9)
College degree or higher	470(31.5)	639(42.8)	282(18.9)	101(6.8)
Menopausal Status					0.189
Post or Perimenopausal	985(40.6)	967(39.9)	357(14.7)	117(4.8)
Premenopausal	108(35.3)	126(41.2)	52(17)	20(6.5)
Baseline Tamoxifen Use					0.321
Current	646(39.3)	668(40.7)	247(15)	81(4.9)
Never	376(42.5)	334(37.8)	128(14.5)	46(5.2)
Past	59(33.9)	81(46.6)	27(15.5)	7(4)
ER/PR status
ER+ or PR+	835(38.9)	865(40.3)	331(15.4)	113(5.3)	0.127
ER−/PR−	238(43.6)	214(39.2)	74(13.6)	20(3.7)
Stage					0.25
I	430(40.5)	438(41.2)	143(13.5)	52(4.9)
II	495(39.5)	489(40.0)	202(16.1)	68(5.4)
III	170(40.6)	167(39.9)	65(15.5)	17(3.3.)
Isoflavone Supplements**					0.001
Yes	17(29.3)	16(27.6)	18(31)	7(12.1)
No	1078(40.3)	1078(40.3)	392(14.6)	130(4.9)

^*Pacific Islander, American Indian/mixed race

^**p-value for differences of isoflavone intake between strata within category